European Journal of Clinical Pharmacology

, Volume 19, Issue 6, pp 423–429

First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man

  • U. Abshagen
  • S. Spörl-Radun
Originals

Summary

Isosorbide-5-mononitrate (IS-5-MN) 5, 10, 20, 30, 40 and 50 mg were administered orally to 2 healthy male volunteers. The pharmacological effect was determined using digital pulse plethysmography and the orthostatic tilting test, and at the same time side effects were monitored. The threshold of oral activity of IS-5-MN was found to be 5 mg. The maximum response was reached with doses of 20–30 mg. The duration of action of this dose was approximately 8 h. Higher doses did not lead to any further increase, but rather to a decrease in the pharmacological response, while the side-effects, such as headaches, dizziness and nausea, became more prominent. In a randomized, double-blind, three-way cross-over study in 11 female volunteers IS-5-MN 30 mg proved to be more potent with respect to pharmacological activity than sustained released ISDN 20 mg (isosorbide dinitrate), whereas there was no difference in side-effects. Thus, it can be estimated that IS-5-MN 20 mg is approximately equivalent to 20 mg sustained released ISDN. IS-5-MN is rapidly absorbed after oral administration and the maximum concentration in serum was reached 1.2±0.2 h after doses of 10 to 50 mg. The pharmacokinetics showed dose-linearity. The compound was eliminated with an average half life of 4.04±0.16 h, which is appropriate for a reasonably prolonged duration of action without the need for a sustained release formulation.

Key words

isosorbide-5-mononitrate isosorbidedinitrate digital pulse plethysmography pharmacodynamics side-effects pharmacokinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mannes GA, Goebel G, Jennerwein G, Rudolph W (1980) Plasmakonzentrationen, Wirkungsdauer und Wirkungsstärke von Lanzeit-Isosorbiddinitrat. In: Rudolph W, Schrey A (eds) Nitrate II. Urban & Schwarzenberg, MünchenGoogle Scholar
  2. 2.
    Michel D (1976) Der Einfluß von Metaboliten des Isosorbid-dinitrats auf das Belastungs-EKG bei Koronarinsuffizienz. Herz Kreisl 8: 444–447Google Scholar
  3. 3.
    Reed DE, May JF, Hart LG, McCurdy DH (1971) Identification of the urinary metabolites of isosorbide-dinitrate in dogs. Arch Int Pharmacodyn 191: 318–336 (1971)Google Scholar
  4. 4.
    Reifart N, Reifart F, Kaltenbach M, Bussmann WD (1981) Vergleich der antianginösen Wirksamkeit und Wirkdauer von oral verabreichtem Isosorbiddinitrat (ISDN), Isosorbid-2-Mononitrat (IS-2-MN) und Isosorbid-5-Mononitrat (JS-5-MN) Med Welt 32/14a: 524–526Google Scholar
  5. 5.
    Rosseel M, Bogaert MG (1973) GLC determination of nitroglycerin and isosorbide dinitrate in human plasma. J Pharm Sci 62: 754–758Google Scholar
  6. 6.
    Schellong F, Lüderitz B (1954) Regulationsprüfung des Kreislaufs. Dr. Dietrich Steinkopff, DarmstadtGoogle Scholar
  7. 7.
    Sisenwine SF, Ruelius HW (1971) Plasma concentrations and urinary excretion of isosorbide dinitrate and its metabolites in the dog. J Pharmacol Exp Ther 176: 296–301Google Scholar
  8. 8.
    Smolen VF, Williams EJ (1977) Recommended guidelines and methodology for the evaluation of pharmacological effectiveness and comparative bioavailability of organic nitrate antianginal drug products. Prog. FDA Contract No. 223-73-3023Google Scholar
  9. 9.
    Smolen VF (1978) Bioavailability and pharmacokinetic analysis of drug responding systems. Annu Rev Pharmacol Toxicol 18: 495–522Google Scholar
  10. 10.
    Spörl-Radun S, Betzien G, Kaufmann B, Liede V, Abshagen U (1980) Effects and pharmacokinetics of isosorbide dinitrate in normal man. Eur J Clin Pharmacol 18: 237–244Google Scholar
  11. 11.
    Stauch M, Grewe N, Nissen H (1975) Die Wirkung von 2- und 5-Isosorbidmononitrat auf das Belastungs-EKG von Patienten mit Koronarinsuffizienz. Verh Dtsch Ges Kreislaufforsch 41: 181–184Google Scholar
  12. 12.
    Stauch M, Grewe N (1980) Die Wirkung von Isosorbiddinitrat, Isosorbid-2- und -5-Mononitrat auf das Belastungs-EKG und auf die Hämodynamik während Vorhofstimulation bei Patienten mit Angina pectoris. In: Rudolph W, Schrey A (eds) Nitrate II. Urban & Schwarzenberg, MünchenGoogle Scholar
  13. 13.
    Wendt RL (1972) Systemic and coronary vascular effects of the 2- and the 5-mononitrate esters of isosorbide. J Pharmacol Exp Ther 180: 723–742Google Scholar
  14. 14.
    Winsor T (1972) Effects of nitrates on the peripheral circulation. In: Gensini GC (ed) The study of systemic coronary and myocardial effects of nitrates. Charles C. Thomas, Springfield ILGoogle Scholar

Copyright information

© Springer-Verlag 1981

Authors and Affiliations

  • U. Abshagen
    • 1
  • S. Spörl-Radun
    • 1
  1. 1.Department of Clinical PharmacologyBoehringer Mannheim GmbHMannheimFederal Republic of Germany

Personalised recommendations